Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open-label Abatacept Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes

NCT03714022
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
South Miami, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers Squibb

NCT01439204
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Oct 20, 2026, 8:52 AM EDT
Completed No phase listed Observational

A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept

NCT01339481
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Anniston, Alabama • Palm Harbor, Florida • Wheaton, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2011 · Synced Oct 20, 2026, 8:52 AM EDT
Active, not recruiting Phase 2 Interventional

Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD

NCT05621759
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Cyclophosphamide, Abatacept, Tacrolimus
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 4 Interventional Results available

Abatacept in Juvenile Dermatomyositis

NCT02594735
View directory record Official record
Conditions
Dermatomyositis
Interventions
Abatacept
Drug
Lead sponsor
George Washington University
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 20, 2026, 8:52 AM EDT
Not listed Phase 4 Interventional

Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression

NCT01875224
View directory record Official record
Conditions
New Onset Diabetes After Transplant, Kidney Transplantation
Interventions
Belatacept, Tacrolimus
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

NCT00119678
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

NCT00455013
View directory record Official record
Conditions
Disorder Related to Renal Transplantation
Interventions
Thymoglobulin, Belatacept, Sirolimus, Tacrolimus, Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 20, 2026, 8:52 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy Participants

NCT05981976
View directory record Official record
Conditions
Healthy Participants
Interventions
Abatacept
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Cypress, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Biological
Lead sponsor
Arthritis & Rheumatic Disease Specialties Research
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Ulcerative Colitis

NCT00410410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
abatacept (ABA), placebo, abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

NCT03841357
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Abatacept Injection, Usual Care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
2 Years to 16 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Double-blind Abatacept, Double-blind Placebo, Open-label Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
44
States / cities
Decatur, Alabama • Paradise, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 2Phase 3 Interventional

Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

NCT01333878
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Subcutaneous Abatacept
Biological
Lead sponsor
Orrin M Troum, M.D. and Medical Associates
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

NCT03882008
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

NCT00048568
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Methotrexate, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
48
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis

NCT00468208
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Abatacept
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 20, 2026, 8:52 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen

NCT01856257
View directory record Official record
Conditions
Primary Renal Allograft Candidate, Kidney Transplantation
Interventions
Anti-thymocyte Globulin (Rabbit), belatacept, methylprednisolone, basiliximab, mycophenolate mofetil, tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871
View directory record Official record
Conditions
Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions
branebrutinib, abatacept, branebrutinib placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Covina, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Switching From Intravenous to Subcutaneous Study

NCT00663702
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 20, 2026, 8:52 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

NCT03086343
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
44
States / cities
Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Oct 20, 2026, 8:52 AM EDT
Withdrawn Phase 2 Interventional

Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study

NCT02027298
View directory record Official record
Conditions
Primary Sjogren's Syndrome, Secondary Sjogren's Syndrome, Inflammatory Arthritis, Rheumatoid Arthritis
Interventions
Abatacept
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 20, 2026, 8:52 AM EDT